- Home
- ENLV vs IRIX Comparison
ENLV vs IRIX Comparison
Compare ENLV & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- IRIX
- Stock Information
- Founded
- ENLV 2005
- IRIX 1989
- Country
- ENLV Israel
- IRIX United States
- Employees
- ENLV N/A
- IRIX N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ENLV Health Care
- IRIX Health Care
- Exchange
- ENLV Nasdaq
- IRIX Nasdaq
- Market Cap
- ENLV 24.4M
- IRIX 27.5M
- IPO Year
- ENLV 1995
- IRIX 1996
- Fundamental
- Price
- ENLV $1.00
- IRIX $1.51
- Analyst Decision
- ENLV Strong Buy
- IRIX Hold
- Analyst Count
- ENLV 2
- IRIX 1
- Target Price
- ENLV $9.50
- IRIX $2.00
- AVG Volume (30 Days)
- ENLV 50.8K
- IRIX 30.8K
- Earning Date
- ENLV 03-28-2025
- IRIX 03-25-2025
- Dividend Yield
- ENLV N/A
- IRIX N/A
- EPS Growth
- ENLV N/A
- IRIX N/A
- EPS
- ENLV N/A
- IRIX N/A
- Revenue
- ENLV N/A
- IRIX $48,431,000.00
- Revenue This Year
- ENLV N/A
- IRIX N/A
- Revenue Next Year
- ENLV N/A
- IRIX $5.44
- P/E Ratio
- ENLV N/A
- IRIX N/A
- Revenue Growth
- ENLV N/A
- IRIX N/A
- 52 Week Low
- ENLV $0.81
- IRIX $1.27
- 52 Week High
- ENLV $4.59
- IRIX $3.65
- Technical
- Relative Strength Index (RSI)
- ENLV 32.92
- IRIX 38.42
- Support Level
- ENLV $1.00
- IRIX $1.46
- Resistance Level
- ENLV $1.09
- IRIX $1.60
- Average True Range (ATR)
- ENLV 0.08
- IRIX 0.05
- MACD
- ENLV -0.00
- IRIX -0.01
- Stochastic Oscillator
- ENLV 12.50
- IRIX 18.75
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.